Legend Biotech Corporation
LEGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.28 | 0.02 | -0.23 |
| FCF Yield | 0.81% | -0.68% | -3.39% | -2.84% |
| EV / EBITDA | -92.57 | -29.80 | -34.19 | 57.93 |
| Quality | ||||
| ROIC | -3.04% | -1.53% | -3.65% | -3.45% |
| Gross Margin | 57.66% | 61.58% | 63.42% | 60.37% |
| Cash Conversion Ratio | -0.74 | 0.10 | 1.05 | -2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 57.35% | 69.15% | 91.75% | 79.59% |
| Free Cash Flow Growth | 206.87% | 78.95% | -25.22% | -8.43% |
| Safety | ||||
| Net Debt / EBITDA | -3.96 | -1.07 | 0.89 | 1.22 |
| Interest Coverage | -7.70 | -4.18 | -10.01 | -14.44 |
| Efficiency | ||||
| Inventory Turnover | 3.95 | 2.75 | 2.31 | 3.09 |
| Cash Conversion Cycle | -56.76 | 44.27 | 42.66 | 44.08 |